Enspryng 120 mg/mL
Satralizumab · INJECTION, SOLUTION · Genentech, Inc.
No Recall History
Plain English
Enspryng is a injection, solution containing satralizumab at 120 mg/mL, taken subcutaneous. Manufactured by Genentech, Inc..
Key Facts
- Brand Name
- Enspryng
- Generic Name
- Satralizumab
- NDC Code (Product)
50242-007- Manufacturer
- Genentech, Inc.
- Strength
- 120 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761149
- Marketing Start
- 08/14/2020
Recall History
No Recall HistoryFrequently Asked Questions
What is Enspryng used for?
Enspryng contains Satralizumab. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is Enspryng a controlled substance?
Enspryng is not classified as a controlled substance by the DEA.
What is the generic name for Enspryng?
The generic name for Enspryng is Satralizumab. There are no other listed brand versions of Satralizumab.
What is the NDC code for Enspryng 120 mg/mL?
The NDC (National Drug Code) for Enspryng 120 mg/mL is 50242-007, listed by Genentech, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)